G
T. Yoshimura et al.
Paper
Synthesis
IR (neat): 3439, 1738, 1612 cm–1
.
HRMS-DART: m/z [M + H]+ calcd for C18H15O2: 263.10720; found:
263.10561.
1H NMR (600 MHz, CDCl3): = 5.96–5.95 (m, 1 H), 5.73–5.72 (m, 1 H),
2.66 (d, J = 17.4 Hz, 1 H), 2.35–2.30 (m, 2 H), 2.18–2.01 (m, 2 H), 1.64
(br s, 1 H), 1.11 (s, 3 H).
(S)-3a-Methyl-3,3a,6,7-tetrahydro-2H-indene-2,4(5H)-dione (17)
MS (DART): m/z = 153 [M + H]+.
To a solution of chiral 4a (20 mg, 0.12 mmol) and 4 Å MS (105 mg) in
CH2Cl2 (1.0 mL) was added PDC (135.4 mg, 0.36 mmol) at 0 °C. After
being stirred at rt for 5.5 h, the mixture was diluted with Et2O and
filtered through a pad of Celite. The filtrate was concentrated to give a
residue that was purified by preparative TLC (hexane/EtOAc = 1:1) to
afford 17 (11.3 mg, 57%) as a colorless oil.
The ee of 13 was determined after its conversion into the correspond-
ing tosyl hydrazone 14.
N'-[(3aS,6aR)-3a-Hydroxy-6a-methyl-3,3a,6,6a-tetrahydropental-
en-1(2H)-ylidene]-4-methylbenzenesulfonohydrazide (14)
[]D28 = –18 (c 0.58, CHCl3, 40% ee) {(R)-1717: Lit. []D20 = +47.3 (c 0.42,
CHCl3)}.
Treatment of 13 (24.6 mg, 0.16 mmol) with TsNHNH2 (33.5 mg, 0.18
mmol) and PPTS (1.5 mg, 0.006 mmol) in THF (3 mL) gave tosyl hy-
drazone 14 (27.3 mg, 53%) as a colorless oil. HPLC conditions: DAICEL
Chiralpak AD-H, hexane/2-propanol = 9:1, flow = 1 mL/min, max
254 nm, t1 = 34.0 min, t2 = 40.9 min.
[]D24 = +13.9 (c 1.17, CHCl3, 13% ee).
IR (neat): 3473, 1653, 1598 cm–1
IR (neat): 1712, 1622 cm–1
.
=
1H NMR (400 MHz, CDCl3): = 5.82 (d, J = 1.6 Hz, 1 H), 2.21 (d, J = 19.0
Hz, 1 H), 2.90–2.69 (m, 3 H), 2.49–2.43 (m, 1 H), 2.32–2.24 (m, 1 H),
2.14 (d, J = 19.0 Hz, 1 H), 1.80–1.67 (m, 1 H), 1.54 (s, 3 H).
MS (DART): m/z = 165 [M + H]+.
.
1H NMR (600 MHz, CDCl3): = 7.82 (d, J = 7.8 Hz, 2 H), 7.44 (br s, 1 H),
7.30 (d, J = 7.8 Hz, 2 H), 5.81 (dt, J = 5.4, 2.6 Hz, 1 H), 5.58 (dt, J = 6.0,
2.0 Hz, 1 H), 2.61 (dt, J = 16.8, 2.1 Hz, 1 H), 2.43 (s, 3 H), 2.41–2.33 (m,
2 H), 2.16–2.12 (m, 1 H), 1.96–1.86 (m, 2 H), 1.65 (br s, 1 H), 1.07 (s, 3
H).
13C NMR (150 MHz, CDCl3): = 171.8, 143.9, 136.2, 135.3, 134.4,
129.4, 127.9, 90.9, 53.6, 45.6, 32.2, 25.6, 21.6, 18.6.
Funding Information
This research was supported by the Japan Society for the Promotion
of Science (JSPS), Grants-in-Aid for Scientific Research (KAKENHI)
(Grant No. JP17K08208).
J
a
p
a
n
S
o
c
i
etyforth
e
Pro
m
oti
o
n
of
S
c
i
e
n
c
e
(J
P
1
7
K
0
8
2
0
8)
HRMS-DART: m/z [M + H]+ calcd for C16H21N2O3S: 321.12729; found:
321.12807.
Supporting Information
Supporting information for this article is available online at
2-(3-Iodoallyl)-2-phenyl-1H-indene-1,3(2H)-dione (15)
S
u
p
p
orit
n
gInformati
o
n
S
u
p
p
orit
n
gInformati
o
n
Compound 15 was synthesized from 2-phenylindane-1,3-dione (400
mg, 1.80 mmol) by following a similar method to that used for the
synthesis of 6b. Compound 15 (490.9 mg, 80%) was obtained as an or-
ange oil.
References
(1) (a) Li, C.; Ragab, S.; Liu, G.; Tang, W. Nat. Prod. Rep. 2020, 37,
276. (b) Xu, P.-W.; Yu, J.-S.; Chen, C.; Cao, Z.-Y.; Zhou, F.; Zhou, J.
ACS Catal. 2019, 8, 1820. (c) Feng, J.; Holmes, M.; Krische, M. J.
Chem. Rev. 2017, 117, 12564. (d) Overman, L. E.; Quasdorf, K. W.
Nature 2014, 516, 181.
(2) (a) Zeng, X.-P.; Cao, Z.-Y.; Wang, Y.-H.; Zhou, F.; Zhou, J. Chem.
Rev. 2016, 116, 7330. (b) Petersen, K. S. Tetrahedron Lett. 2015,
56, 6523. (c) Studer, A.; Schleth, F. Synlett 2005, 3033.
(3) Buchschacher, P.; Fürst, A.; Gutzwiller, J. Org. Synth. 1985, 63,
37.
IR (neat): 1706 cm–1
.
1H NMR (400 MHz, CDCl3): = 8.06–8.02 (m, 2 H), 7.90–7.85 (m, 2 H),
7.44–7.41 (m, 2 H), 7.35–7.26 (m, 3 H), 6.29 (dt, J = 7.2, 1.6 Hz, 1 H),
6.10 (q, J = 7.1 Hz, 1 H), 3.08 (dd, J = 6.9, 1.4 Hz, 2 H).
13C NMR (150 MHz, CDCl3): = 200.4, 141.5, 136.1, 135.7, 135.1,
128.9, 127.9, 127.1, 123.8, 86.4, 60.7, 40.4.
HRMS-DART: m/z [M + H]+ calcd for C18H14IO2: 389.00385; found:
389.00434.
(4) Hajos, Z. G.; Parrish, D. R. Org. Synth. 1985, 63, 26.
(5) Nakazaki, K.; Hayashi, K.; Hosoe, S.; Tashiro, T.; Kuse, M.;
Takikawa, H. Tetrahedron 2012, 68, 9029.
(6) Tang, Y.; Liu, J.; Chen, P.; Ly, M.; Wang, Z.; Huang, Y. J. Org. Chem.
2014, 79, 11729.
(3aR,8aR)-3a-Hydroxy-8a-phenyl-3a,8a-dihydrocyclopenta[a]in-
den-8(1H)-one (16)
Following general procedure 2, compound 15 (81.5 mg, 0.21 mmol)
was converted into 16 (38.4 mg, 60%, 14% ee) as a colorless oil. HPLC
conditions: DAICEL Chiralpak AD-H, hexane/2-propanol = 9:1, flow =
1 mL/min, max = 254 nm, t1 = 8.1 min, t2 = 12.0 min.
(7) (a) Wei, Q.; Cai, J.; Hu, X.-D.; Zhao, J.; Cong, H.; Zheng, C.; Liu,
W.-B. ACS Catal. 2020, 10, 216. (b) Selmani, A.; Darses, S. Org.
Lett. 2020, 22, 2681. (c) Yuan, Z.; Feng, Z.; Zeng, Y.; Zhao, X.; Lin,
A.; Yao, H. Angew. Chem. Int. Ed. 2019, 58, 2884. (d) Zanghi, J. M.;
Liu, S.; Meek, S. J. Org. Lett. 2019, 21, 5172. (e) Zhu, T.; Lui, Y.;
Smetankova, M.; Zhuo, S.; Mou, C.; Chai, H.; Jin, Z.; Chi, Y. R.
Angew. Chem. Int. Ed. 2019, 58, 15778. (f) You, C.; Li, X.; Gong,
Q.; Wen, J.; Zhang, X. J. Am. Chem. Soc. 2019, 141, 14560.
(g) Knowe, M. T.; Danneman, M. W.; Sun, S.; Pink, M.; Johnston,
J. N. J. Am. Chem. Soc. 2018, 140, 1998. (h) Cai, J.; Wei, Q.; Hu, X.-
D.; Zhang, Y.; Li, W.; Cong, H.; Liu, W.; Liu, W.-B. Synthesis 2018,
50, 1661. (i) Wu, X.; Chen, Z.; Bai, Y.-B.; Dong, V. M. J. Am. Chem.
Soc. 2016, 138, 12013. (j) Li, Y.; Yang, S.; Wen, G.; Lin, Q.; Zhang,
[]D25 = –9.2 (c 1.71, CHCl3, 14% ee).
IR (neat): 3423, 1709, 1603 cm–1
.
1H NMR (600 MHz, CDCl3): = 7.83 (d, J = 7.8 Hz, 1 H), 7.78 (d, J = 7.2
Hz, 1 H), 7.72 (t, J = 7.5 Hz, 1 H), 7.50 (t, J = 7.2 Hz, 1 H), 7.32 (t, J = 7.5
Hz, 2 H), 7.25–7.22 (m, 3 H), 5.97–5.93 (m, 2 H), 3.28–3.21 (m, 2 H),
1.85 (s, 1 H).
13C NMR (150 MHz, CDCl3): = 205.8, 156.1, 137.9, 135.8, 135.4,
135.2, 132.6, 129.2, 128.6, 128.1, 127.3, 124.3, 124.2, 91.2, 68.5, 41.8.
© 2020. Thieme. All rights reserved. Synthesis 2020, 52, A–H